Presented to the Subcommittee on Science, Technology, Research and Innovation to Drive the Country of the Science, Technology, Research and Innovation Committee, The House of Representatives, Bangkok, Thailand on July 29, 2020
Presented at the 11th Healthcare CIO Certificate Program, School of Hospital Management, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand on March 24, 2021
KCR: Post-Authorisation Safety Studies (PASS) - Is the Ongoing Surveillance a...KCR
Post-Authorisation Safety Studies (PASS)
Is the Ongoing Surveillance a Blessing Or a Curse?
28th DIA EuroMeeting
7 April 2016, Hamburg, Germany
Magdalena Matusiak, MPharm
Manager, Clinical Development
Pharmacovigilance Team Lead, KCR
Presented at the 11th Healthcare CIO Certificate Program, School of Hospital Management, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand on March 24, 2021
KCR: Post-Authorisation Safety Studies (PASS) - Is the Ongoing Surveillance a...KCR
Post-Authorisation Safety Studies (PASS)
Is the Ongoing Surveillance a Blessing Or a Curse?
28th DIA EuroMeeting
7 April 2016, Hamburg, Germany
Magdalena Matusiak, MPharm
Manager, Clinical Development
Pharmacovigilance Team Lead, KCR
Professor Peivand Pirouzi Inc. - Pharmacovigilance Inspections: Representation of Pharmacovigilance System Master File
Copyright 2015 - Professor Peivand Pirouzi Inc., International Corporate Training, Canada
All rights reserved
Personal Data Protection Act (PDPA) and Enterprise Risk Management (February ...Nawanan Theera-Ampornpunt
Presented at the PDPA for Mahidol University Workshop for Non-Healthcare Faculties by the Division of Information Technology, Office of the President, Mahidol University, Nakhon Pathom, Thailand on February 15, 2021
Pharmacovigilance in USA and Europe_Katalyst HLSKatalyst HLS
Introduction to Drug Safety & Pharmacovigilance in USA and Europe for Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Personal Data Protection Act (PDPA) and Enterprise Risk Management (February ...Nawanan Theera-Ampornpunt
Presented at the PDPA for Mahidol University Workshop for Non-Healthcare Faculties by the Division of Information Technology, Office of the President, Mahidol University, Nakhon Pathom, Thailand on February 1, 2021
Pharmacovigilance Process Work Flow - Katalyst HLSKatalyst HLS
Introduction to Drug Safety & Pharmacovigilance Process Work Flow for Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
After adoption and success of E2B R2 for almost a decade finally change was brought to tear down and bring some more updates to the existing ICSR Elements Design.
Big Data in Drug Safety: Making post-marketing surveillance in pharmacovigila...Arete-Zoe, LLC
The paper makes a case for change in the way data on the safety of medicines is collected, structured, analyzed, visualized, and shared. Post-market surveillance shall move away from active reporting of individual case reports into national and international databases toward the collection and analysis of anonymous structured summary data from health care providers. The objective is to enable an analysis of total numbers of treated patients and treatment outcomes, including adverse drug reactions and off-label drug use, to provide meaningful, population-based, statistically valid, bias-free, real-time information on safety and efficacy of products on the market without endangering patients' privacy. Such approach would significantly reduce privacy concerns and add value for stakeholders who are interested in timely and accurate information on benefit:risk profile of medicinal products.
Literature screening for pharmacovigilance 190818Marnix Wieffer
Biomedical literature is an important source of drug adverse event reporting and Pharmacovigilance. However, due to the high volume of literature, sub-optimal search strategies and regulatory pressure, pharmaceutical companies are struggling to screen biomedical literature in a compliant and cost-effective manner.
This slide deck describes how, through outsourcing, automation and prioritization technology, we can significantly improve efficiency and compliance of literature screening.
TSDP emphasizes on understanding client’s requirements for drafting proposals for preparation of medico-marketing documents. To know more about medical writing training, visit: http://turacozskilldevelopment.org/
In this webinar, Dale Sanders will provide a pragmatic, step-by-step, and measurable roadmap for the adoption of analytics in healthcare-- a roadmap that organizations can use to plot their strategy and evaluate vendors; and that vendors can use to develop their products. Attendees will have a chance to learn about:
1) The details of his eight-level model, 2) A brief introduction to the HIMSS/IIA DELTA Model, 3) The importance of permanent organizational teams to sustain improvements from analytic investments, 4) The process of curating and maturing data governance, and 5) The coordination of a data acquisition strategy with payment and reimbursement strategies
Presented at The Seventh National Conference on Medical Informatics and The Annual Meeting of the Thai Medical Informatics Association (TMI-NCMedInfo 2018), Bangkok, Thailand on November 23, 2018
Professor Peivand Pirouzi Inc. - Pharmacovigilance Inspections: Representation of Pharmacovigilance System Master File
Copyright 2015 - Professor Peivand Pirouzi Inc., International Corporate Training, Canada
All rights reserved
Personal Data Protection Act (PDPA) and Enterprise Risk Management (February ...Nawanan Theera-Ampornpunt
Presented at the PDPA for Mahidol University Workshop for Non-Healthcare Faculties by the Division of Information Technology, Office of the President, Mahidol University, Nakhon Pathom, Thailand on February 15, 2021
Pharmacovigilance in USA and Europe_Katalyst HLSKatalyst HLS
Introduction to Drug Safety & Pharmacovigilance in USA and Europe for Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Personal Data Protection Act (PDPA) and Enterprise Risk Management (February ...Nawanan Theera-Ampornpunt
Presented at the PDPA for Mahidol University Workshop for Non-Healthcare Faculties by the Division of Information Technology, Office of the President, Mahidol University, Nakhon Pathom, Thailand on February 1, 2021
Pharmacovigilance Process Work Flow - Katalyst HLSKatalyst HLS
Introduction to Drug Safety & Pharmacovigilance Process Work Flow for Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
After adoption and success of E2B R2 for almost a decade finally change was brought to tear down and bring some more updates to the existing ICSR Elements Design.
Big Data in Drug Safety: Making post-marketing surveillance in pharmacovigila...Arete-Zoe, LLC
The paper makes a case for change in the way data on the safety of medicines is collected, structured, analyzed, visualized, and shared. Post-market surveillance shall move away from active reporting of individual case reports into national and international databases toward the collection and analysis of anonymous structured summary data from health care providers. The objective is to enable an analysis of total numbers of treated patients and treatment outcomes, including adverse drug reactions and off-label drug use, to provide meaningful, population-based, statistically valid, bias-free, real-time information on safety and efficacy of products on the market without endangering patients' privacy. Such approach would significantly reduce privacy concerns and add value for stakeholders who are interested in timely and accurate information on benefit:risk profile of medicinal products.
Literature screening for pharmacovigilance 190818Marnix Wieffer
Biomedical literature is an important source of drug adverse event reporting and Pharmacovigilance. However, due to the high volume of literature, sub-optimal search strategies and regulatory pressure, pharmaceutical companies are struggling to screen biomedical literature in a compliant and cost-effective manner.
This slide deck describes how, through outsourcing, automation and prioritization technology, we can significantly improve efficiency and compliance of literature screening.
TSDP emphasizes on understanding client’s requirements for drafting proposals for preparation of medico-marketing documents. To know more about medical writing training, visit: http://turacozskilldevelopment.org/
In this webinar, Dale Sanders will provide a pragmatic, step-by-step, and measurable roadmap for the adoption of analytics in healthcare-- a roadmap that organizations can use to plot their strategy and evaluate vendors; and that vendors can use to develop their products. Attendees will have a chance to learn about:
1) The details of his eight-level model, 2) A brief introduction to the HIMSS/IIA DELTA Model, 3) The importance of permanent organizational teams to sustain improvements from analytic investments, 4) The process of curating and maturing data governance, and 5) The coordination of a data acquisition strategy with payment and reimbursement strategies
Presented at The Seventh National Conference on Medical Informatics and The Annual Meeting of the Thai Medical Informatics Association (TMI-NCMedInfo 2018), Bangkok, Thailand on November 23, 2018
Presented at the BDMS Golden Jubilee Scientific Conference 2022 "BDMS Beyond 50 years: Looking towards the centennial," Bangkok Dusit Medical Services Public Company Limited (BDMS), Bangkok, Thailand on October 19, 2022
Presented at The Thai Medical Informatics Association Annual Conference and The National Conference on Medical Informatics (TMI-NCMedInfo) 2021, Bangkok, Thailand on November 26, 2021
Presented at the Master of Science Program in Medical Epidemiology and the Doctor of Philosophy Program in Clinical Epidemiology, Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand on November 25, 2021
Presented at the Master of Science and Doctor of Philosophy Programs in Data Science for Healthcare and Clinical Informatics, Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand on November 15, 2021
Consumer Health Informatics, Mobile Health, and Social Media for Health: Part...Nawanan Theera-Ampornpunt
Presented at the Master of Science and Doctor of Philosophy Programs in Data Science for Healthcare and Clinical Informatics, Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand on November 10, 2021
Consumer Health Informatics, Mobile Health, and Social Media for Health: Part...Nawanan Theera-Ampornpunt
Presented at the Master of Science and Doctor of Philosophy Programs in Data Science for Healthcare and Clinical Informatics, Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand on November 10, 2021
Presented at the Master of Science and Doctor of Philosophy Programs in Data Science for Healthcare and Clinical Informatics, Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand on November 8, 2021
Information Technology Management in Healthcare Organizations: Part 2 (Octobe...Nawanan Theera-Ampornpunt
Presented at the Master of Science and Doctor of Philosophy Programs in Data Science for Healthcare and Clinical Informatics, Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand on October 20, 2021
Information Technology Management in Healthcare Organizations: Part 1 (Octobe...Nawanan Theera-Ampornpunt
Presented at the Master of Science and Doctor of Philosophy Programs in Data Science for Healthcare and Clinical Informatics, Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand on October 20, 2021
2. • Telemedicine (โทรเวชกรรม/การแพทย์ทางไกล)
• tele- (to or at a distance) + medicine/health
• “The use of telecommunications technology for medical
diagnostic, monitoring and therapeutic purposes when
distance and/or time separates the participants.”
• การใช้เทคโนโลยีสารสนเทศ/โทรคมนาคมเพื่อการวินิจฉัย ติดตาม และ
รักษาทางการแพทย์ เมื่อระยะทางหรือเวลาเป็นตัวแยก 2 ฝ่ายออกจาก
กัน
• ในบางกรณี ใช้ telehealth เพื่อให้ครอบคลุมนอกเหนือ medical
encounters (visit ในการดูแลรักษาผู้ป่วย) ด้วย เช่น การให้สุขศึกษา)
Telemedicine & Telehealth
Hersh et al (2006)
4. • Store-and-forward telemedicine
– ใช้เก็บข้อมูลแล้วค่อยส่งต่อในภายหลัง (Collect data then transmit them for
subsequent interpretation) เช่น ส่งภาพให้แพทย์ผู้เชี่ยวชาญวินิจฉัย
• Home-based telemedicine
– ใช้สาหรับดูแลผู้ป่วยที่บ้านหรือที่พัก (Used by health professionals to monitor
physiology, test results, images and sounds, usually collected in a patient’s
home or a nursing facility)
• Office/hospital-based telemedicine
– ใช้สาหรับดูแลผู้ป่วยใน office/clinical setting (Usually real-time clinician-patient
interactions that conventionally would require face-to-face encounters
between a patient and a health professional)
3 Main Types of Telemedicine
Hersh et al (2006)
8. • “Store-and-forward services have been studied in many specialties,
the most common being dermatology, wound care and
ophthalmology. The evidence for their efficacy is mixed.”
• Several limited studies showed the benefits of home-based
telemedicine interventions in chronic diseases. Studies of
office/hospital-based telemedicine suggest that telemedicine is most
effective for verbal interactions, e.g. videoconferencing for diagnosis
and treatment in specialties like neurology and psychiatry.
• There are still significant gaps in the evidence base between where
telemedicine is used and where its use is supported by high-quality
evidence.
The Previous Era of
Telemedicine & Telehealth
Hersh et al (2006)
11. • Current Trends
–Change from using telehealth to increase access to
health care to providing convenience and reducing
cost
–Expansion of telehealth to chronic conditions
–Migration of telehealth from hospitals and clinics to
home and mobile devices
State of TeleHealth
Dorsey & Topol (2015)
12. • Limitations of Telehealth
–Reimbursement
• Limited & fragmented insurance coverage of telehealth
• Potential for excess health care utilization
–Clinical issues
• Patient-physician relationship
• Quality of physical examination
• Quality of care with remote visits than with in-person
visits
State of TeleHealth
Dorsey & Topol (2015)
13. Dorsey & Topol (2015)
• Limitations of Telehealth
–Clinical issues (continued)
•Potential for abuse (e.g. overprescribing of narcotics)
•Fragmentation of care among multiple providers
–Legal issues (e.g., state licensure, liability)
–Social issues (digital divide)
State of TeleHealth
14. Legal Issues
• Privacy & Security Issues
• Liability due to Risks of Medical Errors
▪ Misdiagnosis
▪ Delayed Diagnosis & Treatment
▪ Miscommunication & Information Reliability
• Legal Compliance
▪ พรบ.สถานพยาบาล, พรบ.วิชาชีพ, พรบ.ยา, พรบ.เครื่องมือ
แพทย์ ฯลฯ
▪ Legal Documentation
17. • Health IT as a replacement or supplement of
clinicians?
– The demise of the “Greek Oracle” model (Miller & Masarie, 1990)
The “Greek Oracle” Model
The “Fundamental Theorem” Model
Friedman (2009)
Wrong Assumption
Correct Assumption
Proper Roles of Health IT
31. • ควรทบทวนความจาเป็นในการแก้ไข พรบ.วิชาชีพเวชกรรม หรือ
กฎหมายอื่นๆ ที่เกี่ยวข้อง หรือออก พรบ. Telemedicine ให้
ชัดเจน โดยหารือกันระหว่างหน่วยงานต่างๆ และนักวิชาการ
• Telemedicine Providers เริ่มเปิดให้บริการแล้ว ต้อง
monitor case ร้องเรียน หรือปัญหาที่เกิดขึ้น
Next Steps on Telemedicine
คณะอนุกรรมการพิจารณาแนวทางการใช้สื่อสารสนเทศทางการแพทย์ของผู้ประกอบวิชาชีพเวชกรรม แพทยสภา (2560-2561) (ยังไม่ใช่ Official Position)
32. • Disease-specific & specialty-specific telemedicine
medical practice guidelines (review of evidence &
balancing risk-benefits)
• Medical records documentation guidelines
• Security, privacy & identification/authentication
standards
• Harmonization among regulators
• Professional telemedicine training/certification?
Next Steps on Telemedicine
คณะอนุกรรมการพิจารณาแนวทางการใช้สื่อสารสนเทศทางการแพทย์ของผู้ประกอบวิชาชีพเวชกรรม แพทยสภา (2560-2561) (ยังไม่ใช่ Official Position)
43. 3 Areas of Health IT
Patients &
Consumers
Providers & Patients
Healthcare Managers,
Policy-Makers,
Payers,
Epidemiologists,
Researchers
Copyright Nawanan Theera-Ampornpunt (2018)
Clinical
Informatics
Public
Health
Informatics
Consumer
Health
Informatics
44. Some Categories of “Health IT”
Providers
Patients &
Consumers
Electronic Health
Records (EHRs/EMRs)
Hospital Information
Systems (HIS)
mHealth
Management Information
Systems (such as Enterprise
Resource Planning)
Personal Health Records
(PHRs)
Telemedicine
Wearable Devices
“Smart Homes” IoT
mHealthWeb & Social Media
“Consumer Health
Informatics”
“Clinical Informatics”
Health Information
Exchange (HIE)